Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02294513
Other study ID # CHPHST101659-03HIAD
Secondary ID
Status Completed
Phase N/A
First received October 31, 2014
Last updated April 10, 2017
Start date October 2014
Est. completion date February 2017

Study information

Verified date April 2017
Source Phonak AG, Switzerland
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

There is a strong connection between hearing loss and cognitive impairment, particularly dementia, in old age. Worldwide, dementia affects approximately 5% of persons over the age of 65 years. Hearing loss is even more prevalent in old age, affecting an estimated one third of persons over the age of 65 years. Thus, there is likely a large degree of overlap between the impairments. Indeed, this overlap may influence older adults' everyday functioning, communication, social engagement and quality of life, as well as influencing the well-being of their family caregivers. This project will examine whether patients with hearing loss and Alzheimer's disease, the most common form of dementia, derive benefit the from hearing aids prescribed and fit to them following current best practice procedures in a geriatric audiology clinic. For the first time, a formal evaluation of the potential benefits of hearing aids for the patients' family caregivers will also be conducted.


Description:

Currently, five percent of individuals over the age of 65 suffer from Alzheimer's disease (AD) or a related dementia. Given that hearing loss affects approximately one third of individuals over the age of 65, it is likely that many persons with AD will also suffer from co-morbid hearing loss. Following this logic, a small proportion of the patients treated in a geriatric audiology clinic most likely have both AD and hearing loss. Little research has examined the use of hearing aids by persons with AD, and whether current audiologic rehabilitation can provide benefits for their cognitive, social, and communication functioning. In addition, given that caregiver burden is a huge issue for caregivers of persons with AD, this study will examine whether providing hearing aids to those with AD has concomitant benefits for their family caregivers (e.g., spouse, adult child).

The main research question in this study is: Will persons with AD demonstrate benefit from the use of hearing aids, where benefit is measured through questionnaires assessing activities of daily living, communication, and social functioning. We hypothesize that participants with AD in the intervention group (i.e., those who receive hearing aids) will have a larger improvement in overall functioning at the end of a one-month and three-month period than participants with AD in two control groups. Furthermore, we hypothesize that a group of cognitively normal control participants will demonstrate similar gains in functioning to those participants with AD. Finally, we hypothesize that a similar disparity in benefit between the intervention and control groups will be seen for the participants' caregivers. The specific objectives for this project are to determine, for people with AD if … a) they can benefit from hearing aids based on common audiologic outcome measures, as well as measures of communication function and activities of daily living, and if such benefits depend on variations in current audiologic practice; b) they can benefit from hearing aids with regard to measures of severity of cognitive, behavioural and psychological symptoms of dementia and related caregiver burden; c) hearing aids can bolster their family caregivers' psychological well-being, relationship with, and perceived burden related to caring for and communicating with someone who suffers from both AD and hearing loss, and if specific issues related to communication and audiologic rehabilitation are identified as important by caregivers; and d) the beneficial effects of the hearing aid intervention on the person and their caregiver can be maintained at three months post-fitting.

A randomized control design will be used with three groups of AD patients randomly assigned to 1) intervention (immediate hearing aid fitting), 2) wait-list control (no hearing aid intervention) or 3) active control (no hearing aid intervention + using a new form of fitness technology). A final group of controls with normal cognition will also be tested. All participants will undergo an assessment of their cognition. They and their family caregivers will complete a battery of measures on at least three occasions: once right before the hearing aid fitting is completed to provide a baseline (1), as well as one-month (2) and three-months (3) post-fitting. Participants in the control groups will also complete a set of additional assessments corresponding to the timeline for the hearing aid fitting of participants in the interventions groups (i.e., they will complete 5 assessments rather than 3). In addition to the study sessions, all participants will also complete standard audiology appointments including hearing testing, hearing aid evaluation, hearing aid fitting, and hearing aid checking.


Recruitment information / eligibility

Status Completed
Enrollment 25
Est. completion date February 2017
Est. primary completion date February 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria:

- Referred to the Audiology department by a physician with a confirmed diagnosis of Alzheimer's disease (or no diagnosis of AD if a normal cognition participant)

- Pure-tone threshold at 3 kHz in excess of 35 dB HL in the worse ear

- 60 years of age or older

- Able to read and communicate well in English

- Allow the researchers access to their medication list throughout the study to assess any changes in medications

- Willing to use one or more hearing aid(s) on a regular basis

- Has a caregiver who…

- Is a family member

- Is over the age of 18

- Is able to read and communicate well in English.

- Accompanies participant to Baycrest for all necessary appointments

- Provides qualitative and quantitative assessments of the participant's everyday behaviours and functioning

- Is willing to learn and support the participant in using hearing aid(s), provide information on their own well-being and communication function

- If they currently use one or more hearing aid(s), have acquired said aid(s) at least one year prior and are using it/them in a stable fashion.

Exclusion Criteria:

- Suffered a traumatic brain injury or stroke within the past five years

- Has a history of untreated psychiatric illness

- Has an uncorrected deficit in visual acuity or an untreated visual medical issue (e.g., glaucoma, macular degeneration, diabetic retinopathy)

- Suffers from a neurological disorder (e.g., multiple sclerosis, epilepsy)

- Has any untreated medical conditions that could jeopardize participation in the study

- Has been taking medication for their cognitive impairment (e.g., cholinesterase inhibitor, NMDA receptor antagonists) for less than one month.

- Has a caregiver who…

- Is not cognitively stable (e.g., has been diagnosed with mild cognitive impairment or dementia)

- Has a terminal medical or untreated psychiatric conditions that could jeopardize their participation in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Standard audiologic rehabilitation (incl. HI)
The intervention consists of standard audiologic rehabilitation in which participants are fit with at least one hearing instrument (HI).

Locations

Country Name City State
Canada Baycrest Center of Geriatric Care Toronto Ontario

Sponsors (3)

Lead Sponsor Collaborator
Phonak AG, Switzerland Baycrest Centre for Geriatric Care, University of Toronto

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Client Oriented Scale of Improvement (COSI): Change over 3months Measure of communication situations where the participant experiences difficulty (e.g., at church, in a noisy restaurant). Charts change in difficulty over time 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Primary Hearing Handicap Inventory of the Elderly (HHIE): Change over 3months Measure of hearing and communication handicap 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Primary International Outcome Inventory for Hearing Aids (IOI-HA): Change over 2months Measure of the effectiveness of hearing aid treatments 1st, 3rd month for AD_HI & NC_HI (4th, 6th month for controls AD_WaitC & AD_ActC resp.)
Primary Self-Assessment of Communication (SAC): Change over 3months Measure of difficulties caused by an individual's hearing los 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Primary Satisfaction with Amplification in Daily Life (SADL): Change over 2months Measure of satisfaction with using hearing aids 1st, 3rd month for AD_HI & NC_HI (4th, 6th month for controls AD_WaitC & AD_ActC resp.)
Primary Significant Other Assessment of Communication (SOAC): Change over 3months Completed by significant other, measure of a communication partner's hearing difficulties 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Primary Significant Other Scale for Hearing Disability (SOS-Hear): Change over 3months Measure of third-party disability experienced by spouses of older people with hearing impairment 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Words-in-noise test (WIN): Change over 3months Determines the signal-to-noise (SNR) threshold at which the person can correctly recognize 50% of the target words 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Dichotic digits test (DDT): Change over 3months Measure of central auditory processing 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Montreal Cognitive Assessment (MoCA): Change over 3months Measure of cognitive status 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Hopkins Verbal-Learning Test (HVLT): Change over 3months Measure of verbal memory 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Brief Visuospatial Memory Test-R (BVMT): Change over 3months Measure of visual memory 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Behavioural Pathology in Alzheimer's disease (BEHAVE-AD): Change over 3months Measure of problem behaviours demonstrated by individuals with dementia 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Neuropsychiatric Inventory Brief (NPI-Q): Change over 3months Measure of 12 neuropsychiatric symptoms commonly experienced by individuals with dementia 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Positive and Negative Affect Schedule (PANAS): Change over 3months Measure of mood assessing frequency of 10 positive and 10 negative emotions 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Geriatric Depression Scale- Short Form (GDS-S): Change over 3months Measure of depression in older adults 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Bristol Activities of Daily Living Scale: Change over 3months Measure of instrumental and basic activities of daily living over the past two weeks 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Activity and Social Participation Assessment: Change over 3months Measure of the frequency of specific activities 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Quality of Life in Alzheimer's disease: Change over 3months Measure of the domains of physical health, energy, mood, living situation, memory, family, marriage, friends, chores, fun, money, self, and life as a whole 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Practical Hearing Test- Revised: Change over 2months Measure of objective ability to use hearing aids 1st, 3rd month for AD_HI & NC_HI (4th, 6th month for controls AD_WaitC & AD_ActC resp.)
Secondary Measure of Audiologic Rehabilitation Self-Efficacy for Hearing Aids: Change over 3months Measure of ability to use and maintain hearing aid 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Perception of Conversation Index- Dementia of the Alzheimer Type: Change over 3months Measure of caregivers' strategies for overcoming conversation difficulties 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Relationship Satisfaction Questionnaire (RAS): Change over 3months Measure of satisfaction with primary relationship 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Social Support Questionnaire: Change over 3months Measure of level of social support 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Zarit Burden Interview- Short Form: Change over 3months Measure of burden associated with behavioural impairments and the situation at home 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Short-Form Health Survey-12 items: Change over 3months Measure of functional health and well-being 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
Secondary Hours of hearing aid use: Change over 3months Measure of how many hours the participant is wearing their hearing aid daily 0, 1st, 3rd month (plus 4th and 6th month for controls AD_WaitC & AD_ActC)
See also
  Status Clinical Trial Phase
Completed NCT04079803 - PTI-125 for Mild-to-moderate Alzheimer's Disease Patients Phase 2
Completed NCT04044495 - Sleep, Rhythms and Risk of Alzheimer's Disease N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Recruiting NCT04520698 - Utilizing Palliative Leaders In Facilities to Transform Care for Alzheimer's Disease N/A
Active, not recruiting NCT04606420 - Can Lifestyle Changes Reverse Early-Stage Alzheimer's Disease N/A
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Terminated NCT03672474 - REGEnLIFE RGn530 - Feasibility Pilot N/A
Completed NCT03430648 - Is Tau Protein Linked to Mobility Function?
Recruiting NCT05557409 - A Study to Assess the Efficacy and Safety of AXS-05 in Subjects With Alzheimer's Disease Agitation Phase 3
Recruiting NCT04949750 - Efficacy of Paper-based Cognitive Training in Vietnamese Patients With Early Alzheimer's Disease N/A
Recruiting NCT04522739 - Spironolactone Safety in African Americans With Mild Cognitive Impairment and Early Alzheimer's Disease Phase 4
Recruiting NCT05288842 - Tanycytes in Alzheimer's Disease and Frontotemporal Dementia
Completed NCT06194552 - A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07 Phase 1
Completed NCT03239561 - Evaluation of Tau Protein in the Brain of Participants With Alzheimer's Disease Compared to Healthy Participants Early Phase 1
Completed NCT03184467 - Clinical Trial to Evaluate the Efficacy and Safety of GV1001 in Alzheimer Patients Phase 2
Active, not recruiting NCT03676881 - Longitudinal Validation of a Computerized Cognitive Battery (Cognigram) in the Diagnosis of Mild Cognitive Impairment and Alzheimer's Disease
Terminated NCT03487380 - Taxonomic and Functional Composition of the Intestinal Microbiome: a Predictor of Rapid Cognitive Decline in Patients With Alzheimer's Disease N/A
Completed NCT05538455 - Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases N/A
Recruiting NCT05328115 - A Study on the Safety, Tolerability and Immunogenicity of ALZ-101 in Participants With Early Alzheimer's Disease Phase 1
Completed NCT05562583 - SAGE-LEAF: Reducing Burden in Alzheimer's Disease Caregivers Through Positive Emotion Regulation and Virtual Support N/A